跳至主要内容
临床试验/EUCTR2018-002168-14-NL
EUCTR2018-002168-14-NL进行中(未招募)1 期

Validation of USPIO-enhanced MRI for detection of lymph node metastases in head and neck carcinoma: a pilot study. - Validation of nano-MRI in head and neck carcinoma.

Radboudumc0 个研究点目标入组 25 人开始时间: 2018年12月11日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Radboudumc
入组人数
25

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • - Males and females aged >18 years.
  • - Patients with histopathologically proven cT0-4N0-2M0 squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or unknown primary.
  • - Patients planned for a neck dissection.
  • - Patients providing informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 25
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 25

排除标准

  • - Patients who underwent radio- and/or chemotherapy to the neck before surgery.
  • - Patients who had a previous lymphadenectomy in the head and neck region.
  • - Patients who are pregnant and/or breast-feeding.
  • Patients with contraindications to MRI:
  • - Epilepsy
  • - Metallic implants
  • Patients with contraindications to ferumoxtran-10:
  • - prior allergic reaction to ferumoxtran-10 or any other iron preparation
  • - prior allergic reaction contributed to dextran or other polysaccharide, in any preparation
  • - prior allergic reaction to contrast media of any type
  • - hereditary hemochromatosis, thalassemia, sickle cell anemia

研究者

发起方
Radboudumc

相似试验